COVID-19 Infection at Samusocial in Paris: Descriptive and Serological Survey
- Conditions
- SARS-COV2 Infection
- Interventions
- Diagnostic Test: blood test for SARS-COV2 serology
- Registration Number
- NCT04470648
- Lead Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
- Brief Summary
Study of COVID-19 seroprevalence in precarious population living in shelters of Samusocial de Paris and in staff working in these centers during COVID-19 epidemic.
- Detailed Description
After emergence of a new coronavirus (Severe Acute Respiratory Syndrome Coronavirus 2, SARS-CoV2) responsible for a cluster of respiratory infection at Wuhan, China, on January, 7th 2020, first cases were diagnosed in France in January 24th 2020.
Health care components of Samusocial de Paris (Lits Haltes Soins Santé (LHSS)) were created in 2006. They provide medical care for homeless people and people in social distress not needing an hospitalization. Sometimes there are 3 persons in a bedroom.
In december 2018, a special shelter for isolated women or women in precarious situations opened.
Because of the living conditions in these centers and the difficulty for these populations to respect social distancing and hygiene recommendations.
A first case of COVID-19 was identified on March 8th 2020 in one of these healthcare centers. Other cases were detected in the same center, then in another center on March 16th, then in the dormitory of the women shelter on March 30th.
A recent study showed an important prevalence of SARS-COV2 in residents of a homeless shelter in Boston (36%), most of them were asymptomatic.
Seroprevalence studies are done in general population or in health care workers, but don't include vulnerable people.
It seemed important to us to describe the epidemic in these centers and to study COVID-19 seroprevalence in these particular populations.
Recruitment & Eligibility
- Status
- COMPLETED
- Sex
- All
- Target Recruitment
- 179
- to have been hosted or working in one the three centers (LHSS Ridder-Plaisance or Saint Michel or Halte femmes) between march and may 2020
- to be aged 18 y or more
- to be able to give an informed consent
- people who refuse to participate
- not being able to give an informed consent
- Person subject to a legal protection measure (safeguard of justice, curatorship or guardianship)
- Person who does not understand the information provided on how to carry out the research
- Obstacle to venous sampling
Study & Design
- Study Type
- OBSERVATIONAL
- Study Design
- Not specified
- Arm && Interventions
Group Intervention Description hosted in the center and HCWs at the epidemic period blood test for SARS-COV2 serology people hosted in the health care or in the women center and health care workers working in one these centers during the epidemic time. People with initial positive SARS-COV2 serology will have a second blood test to mesure atibodies kinetic
- Primary Outcome Measures
Name Time Method SARS-COV-2 seroprevalence in 3 centers for homeless and people in social distress 6 months Primary objective is to evaluate SARS-COV2 seroprevalence in people hosted and health care workers of 3 centers of Samusocial de Paris where COVID19 epidemics occured
- Secondary Outcome Measures
Name Time Method Covid-19 related death rate in the 3 centers from March to May 2020 6 months Number of deaths related to Covid-19 during the epidemic in the 3 centers
Ratio of negative serology rate and positive serology rate in the 3 centers 6 months kinetics of SARS-COV2 antibodies in people with initial positive serology 10 months 2 blood tests 4 and 8 months afetr the first one
Morbidity rate 6 months Measure of morbidity in the participating population in the 3 centers
Ratio of SARS-COV2 seroprevalence obtained in these centers to the estimated seroprevalence in the Ile de France region 6 months
Trial Locations
- Locations (3)
Haltes pour femmes
🇫🇷Paris, France
LHSS Saint-Michel
🇫🇷Paris, France
LHSS Ridder-Plaisance
🇫🇷Paris, France